Institute for Micromanufacturing, Louisiana Tech University, Louisiana, USA.
Biosens Bioelectron. 2012 Oct-Dec;38(1):382-8. doi: 10.1016/j.bios.2012.06.029. Epub 2012 Jun 26.
Herein we report the label-free detection of a cancer biomarker using newly developed arrayed nanostructured Fabry-Perot interferometer (FPI) microchips. Specifically, the prostate cancer biomarker free prostate-specific antigen (f-PSA) has been detected with a mouse anti-human PSA monoclonal antibody (mAb) as the receptor. Experiments found that the limit-of-detection of current nanostructured FPI microchip for f-PSA is about 10 pg/mL and the upper detection range for f-PSA can be dynamically changed by varying the amount of the PSA mAb immobilized on the sensing surface. The control experiments have also demonstrated that the immunoassay protocol used in the experiments shows excellent specificity and selectivity, suggesting the great potential to detect the cancer biomarkers at trace levels in complex biofluids. In addition, given its nature of low cost, simple-to-operation and batch fabrication capability, the arrayed nanostructured FPI microchip-based platform could provide an ideal technical tool for point-of-care diagnostics application and anticancer drug screen and discovery.
在这里，我们报告了使用新开发的阵列纳米结构法布里-珀罗干涉仪（FPI）微芯片对癌症生物标志物进行无标记检测。具体来说，使用作为受体的抗人 PSA 单克隆抗体（mAb）检测前列腺癌生物标志物游离前列腺特异性抗原（f-PSA）。实验发现，当前纳米结构 FPI 微芯片检测 f-PSA 的检测限约为 10pg/mL，并且通过改变固定在传感表面上的 PSA mAb 的量，可以动态改变 f-PSA 的上检测范围。对照实验还表明，实验中使用的免疫分析方案表现出优异的特异性和选择性，这表明在复杂生物流体中痕量检测癌症生物标志物具有巨大潜力。此外，由于其低成本、易于操作和批量制造能力，基于阵列纳米结构 FPI 微芯片的平台可为即时诊断应用和抗癌药物筛选和发现提供理想的技术工具。
